Published in:
01-02-2021 | Influenza Vaccination | Letter to the Editor
COVID-19 vaccination in immunocompromised patients
Authors:
Bhavin Sonani, Fawad Aslam, Amandeep Goyal, Janki Patel, Pankaj Bansal
Published in:
Clinical Rheumatology
|
Issue 2/2021
Login to get access
Excerpt
Almost 1 year into the coronavirus disease 2019 (COVID-19) pandemic, and after more than 50 million cases and 1.35 million deaths globally, reports of the successful conclusion of phase III trials of two vaccines, BNT162b2 and mRNA1273, are most welcoming. Results from phase I/II for both these vaccines were highly encouraging with strongly elicited humoral as well as cellular responses, and no trial-limiting safety concerns [
1,
2]. According to the preliminary data release, both vaccines have been reported to be almost 95% effective in preventing COVID-19 in their phase II/III trials [
3,
4]. Further, the risk of severe illness from COVID-19 has been reported to be lowered by more than 90% after vaccination in both clinical trials [
3,
4]. …
